Edition:
United States

Illumina Inc (ILMN.O)

ILMN.O on Nasdaq

200.60USD
1:07pm EDT
Change (% chg)

$0.35 (+0.18%)
Prev Close
$200.24
Open
$199.69
Day's High
$201.94
Day's Low
$199.69
Volume
367,393
Avg. Vol
936,839
52-wk High
$214.34
52-wk Low
$119.37

Summary

Name Age Since Current Position

Jay Flatley

64 2016 Executive Chairman of the Board

Francis deSouza

46 2016 President, Chief Executive Officer, Director

Sam Samad

47 2016 Chief Financial Officer, Senior Vice President

Marc Stapley

47 2016 Executive Vice President, Chief Administrative Officer

Garret Hampton

51 2017 Executive Vice President - Clinical Genomics

Omead Ostadan

45 2015 Executive Vice President - Operations, Products and Strategy

Mostafa Ronaghi

47 2008 Chief Technology Officer, Senior Vice President

Charles Dadswell

57 2013 Senior Vice President, General Counsel, Secretary

Mark Van Oene

2017 Senior Vice President, Chief Commercial Officer

Arthur Bowman

70 2016 Lead Independent Director

Caroline Dorsa

57 2017 Director

Philip Schiller

56 2016 Director

John Thompson

67 2017 Director

Frances Arnold

60 2016 Independent Director

Daniel Bradbury

56 2004 Independent Director

Karin Eastham

67 2004 Independent Director

Robert Epstein

62 2012 Independent Director

Roy Whitfield

63 2007 Independent Director

Biographies

Name Description

Jay Flatley

Mr. Jay T. Flatley serves as Executive Chairman of the Board of the Company. Effective July 5, 2016. He was Chief Executive Officer, Director of Illumina, Inc. Prior to joining Illumina, Mr. Flatley was co-founder, President, Chief Executive Officer, and a director of Molecular Dynamics, Inc., a NASDAQ-listed life sciences company focused on genetic discovery and analysis, from 1994 until its sale to Amersham Pharmacia Biotech Inc. in 1998. He served in various other positions of increasing responsibility with Molecular Dynamics from 1987 to 1994. From 1985 to 1987, Mr. Flatley was Vice President of Engineering and Vice President of Strategic Planning at Plexus Computers, a UNIX computer company. Mr. Flatley also serves as a director of Coherent, Inc. a NASDAQ-listed provider of photonics-based solutions to commercial and scientific research markets. Mr. Flatley holds a B.A. in Economics from Claremont McKenna College and a B.S. and M.S. in Industrial Engineering from Stanford University.

Francis deSouza

Mr. Francis A. deSouza is President, Chief Executive Officer, Director of Illumina, Inc. Mr. deSouza has served as President since December 2013 and as a Director since January 2014. Prior to joining Illumina, Mr. deSouza was President, Products and Services, of Symantec Corporation, a NASDAQ-listed software technology company, from 2011 to 2013, and Mr. deSouza served as Symantec’s Senior Vice President, Enterprise Security Group, from 2009 to 2011. Prior to joining Symantec, from 2001 to 2006, he was Founder and Chief Executive Officer of IMlogic, Inc. an enterprise instant messaging software company that was acquired by Symantec in 2006, and Mr. deSouza served as Product Unit Manager, Real-time Collaboration Group, at Microsoft Corporation from 1998 to 2001. Prior to joining Microsoft, from 1997 to 1998, Mr. deSouza was co-founder and Chief Executive Officer of Flash Communications, an enterprise instant messaging company that was acquired by Microsoft in 1998. Mr. deSouza is Chairman of the board of directors of MedHelp International, a privately-held online health community. Mr. deSouza received a bachelor’s degree in electrical engineering and computer science with a minor in economics and a master’s degree from Massachusetts Institute of Technology.

Sam Samad

Mr. Sam A. Samad serves as Chief Financial Officer, Senior Vice President of the Company. Mr. Samad, most recently served as Senior Vice President and Corporate Treasurer at Cardinal Health from 2012 to 2016 where, in addition to treasury, he also had leadership responsibility for Cardinal Health’s China business. From 2009 to 2012 he served as Senior Vice President and CFO of Cardinal Health’s Pharmaceutical Segment, and from 2007 to 2009 he served as Vice President, Finance of Cardinal Health’s Supply Chain Services. Prior to joining Cardinal Health in 2007, Mr. Samad held finance roles at Eli Lilly and Pepsico Inc. Mr. Samad holds a BBA degree from American University of Beirut in Lebanon and an MBA from McMaster University in Hamilton, Canada.

Marc Stapley

Mr. Marc A. Stapley serves as Executive Vice President, Chief Administrative Officer of Illumina, Inc. Mr. Stapley was Chief Financial Officer of the Company. Mr. Stapley joins Illumina from Pfizer where he served as Senior Vice President responsible for global financial processes and systems, integration efforts in both the Wyeth and King Pharmaceutical acquisitions and providing oversight to the company’s technology investment program. Prior to Pfizer, he served in a variety of senior finance roles at Alcatel-Lucent, including Americas CFO. He also worked as Finance Director and Controller for several groups at Cadence Design Systems. Stapley began his career as an Auditor at Coopers & Lybrand. Mr. Stapley holds a First Class BSc (Honors) in Mathematics from The University of Reading (England) and is a member of the Institute of Chartered Accountants in England and Wales.

Garret Hampton

Mr. Garret Hampton, Ph.D. has been appointed as Executive Vice President - Clinical Genomics of the Company effective January 9, 2017. Garret will be responsible for leading the clinical genomics group, including the reproductive and genetic health and oncology businesses, regulatory, clinical and medical affairs, CLIA labs, and the Chief Medical Officer's organization. He joins Illumina from Genentech, Inc. where he was Global Head of Oncology Biomarker Development and Companion Diagnostics, co-led the Roche Personalized Medicine R&D Initiative and chaired the Roche/Foundation Medicine Joint R&D Committee. He previously held scientific and management roles at Celgene Corporation, Genomics Institute of the Novartis Research Foundation, and University of California at San Diego. Garret holds a BA in natural sciences and genetics and MA in natural sciences from Trinity College in Dublin, Ireland, and a PhD in cancer genetics from Imperial Cancer Research Fund and the University College London.

Omead Ostadan

Mr. Omead Ostadan is Executive Vice President - Operations, Products and Strategy of the company. Prior to that he served as Senior Vice President, Operations and Development. He is Senior Vice President, Product Development from 2011 to 2015.

Mostafa Ronaghi

Dr. Mostafa Ronaghi, Ph.D. is Chief Technology Officer, Senior Vice President of Illumina, Inc. Dr. Ronaghi joined Illumina in August 2008; 2002 – 2008: principal investigator at Stanford University, where Dr. Ronaghi focused on the development of novel tools for molecular diagnostic applications; 2007 – 2008: chairman and chief scientific officer for Avantome, Inc. a privately-held sequencing company co-founded by Dr. Ronaghi and acquired by Illumina in 2008.

Charles Dadswell

Mr. Charles E. Dadswell is Senior Vice President, General Counsel, Secretary of Illumina, Inc. since April 22, 2013. Mr. Dadswell joins Illumina with more than 20 years of leadership and legal experience at health care-focused technology companies. Most recently, he was Vice President, General Counsel for North and Latin America and Corporate Director of Global Intellectual Property at bioMerieux. In this role, he was responsible for global intellectual property matters and legal matters in North and Latin America. Prior to bioMerieux, he was General Counsel of BioDelivery Sciences International, a specialty pharmaceutical company; and oversaw US intellectual property in a variety of positions with Glaxo, GlaxoWellcome and GlaxoSmithKline. Mr. Dadswell holds a LLM in patent law and trade regulation from The George Washington University Law School, a JD from the Thomas M. Cooley Law School and a bachelor's in science from Ferris State University.

Mark Van Oene

Mr. Mark Van Oene serves as Senior Vice President, Chief Commercial Officer of the Company. Van Oenewas previously the Company's Senior Vice President of the Americas region and subsequently named interim Chief Commercial Officer in late 2016. He will be responsible for worldwide sales, services, and marketing at the Company.

Arthur Bowman

Mr. Arthur Blaine Bowman is Lead Independent Director of Illumina, Inc. since March 2016. He served as Independent Director between 2007 to 2016. Mr. Bowman was formerly the Chairman, President, and Chief Executive Officer of Dionex Corporation, a NASDAQ-listed manufacturer of analytical instruments. Mr. Bowman retired as President and Chief Executive Officer of Dionex in 2002 and as Chairman of the Board in 2005, and he remained a director of Dionex until its sale to Thermo Fisher Scientific Inc. in 2011. He joined Dionex in 1977 and was named President and Chief Executive Officer in 1980. Before joining Dionex, Mr. Bowman was a management consultant with McKinsey & Company, a management consulting firm, and a product engineer with Motorola Semiconductor Products Division, a communication equipment company. Mr. Bowman also serves as a director of Altera Corporation, a NASDAQ-listed provider of programmable logic solutions, and ProteinSimple, a privately-held life sciences company focused on protein research through the use of nanoproteomics. He also served as a past director of Molecular Devices Corporation, a NASDAQ-listed supplier of instruments and consumables for life science researchers, from 1985 until its sale to MDS Inc. in 2007, and of Solexa, Inc. from 2006 until its sale to Illumina in 2007. Mr. Bowman received his B.S. in Physics from Brigham Young University and an M.B.A. from Stanford University.

Caroline Dorsa

Ms. Caroline D. Dorsa serves as Director of the Company. Ms. Dorsa has held a number of senior management positions at Merck & Co. Inc, including Senior Vice President of Marketing Strategy and Integration, and Vice President and Treasurer, where she also oversaw investor relations, financial planning for manufacturing and tax. Most recently, as Executive Vice President and CFO at Public Service Enterprise Group, Ms. Dorsa led the finance, business development, and investor relations teams. She is a Director of Biogen Inc. and Intellia Therapeutics, Inc. and a trustee of the Goldman Sachs MLP Income Opportunities Fund and the Goldman Sachs MLP and Energy Renaissance Fund. In addition to her service at Merck & Co. Inc. and at Public Service Enterprise Group, Ms. Dorsa served as Senior Vice President and CFO of Avaya, Inc. She received her B.A. from Colgate University and her M.B.A. from Columbia University.

Philip Schiller

Mr. Philip W. Schiller is Director of the Company. Schiller has more than 30 years of marketing and management experience, including over 25 at Apple in various marketing positions; as the Vice President of Product Marketing at Macromedia, Inc. of San Francisco, Calif. as the Director of Product Marketing at FirePower Systems, Inc. of Menlo Park, Calif. as an Information Technology Manager at Nolan, Norton & Company of Lexington, Mass. and as a Programmer and Systems Analyst at Massachusetts General Hospital in Boston. He graduated with a B.S. in biology from Boston College.

John Thompson

Mr. John Wendell Thompson has been appointed as Director of the Company, with effect from May 3, 2017. He bringing extensive technology leadership experience to the company. Mr. Thompson’s executive leadership experience includes having served in chief executive officer roles at Symantec and Virtual Instruments, as well as 28 years of prior leadership experience at IBM where he held senior roles in sales, marketing, software development, and as general manager of IBM Americas. He is chairman of the board at Microsoft and has served on the corporate boards of Symantec, NIPSCO (Northern Indiana Public Service Company), Fortune Brands, Seagate Technologies, and United Parcel Service (UPS). Mr. Thompson is a member of the board of trustees for the Wetlands America Trust and formerly a member of the national board of Teach for America. In addition, he has served on several government commissions including the Financial Crisis Inquiry Commission, the National Infrastructure Advisory Council, and the Silicon Valley Blue Ribbon Task Force on Aviation Security and Technology. Mr. Thompson received his B.A. in business administration from Florida A&M University and his M.A. in management science from MIT’s Sloan School of Management.

Frances Arnold

Dr. Frances Arnold is Independent Director of the Company. Dr. Arnold manages a research group at the California Institute of Technology and is the Dick and Barbara Dickinson Professor of Chemical Engineering, Bioengineering and Biochemistry at the California Institute of Technology and Director of the Donna and Benjamin M. Rosen Bioengineering Center. She joined the California Institute of Technology in 1986 and has served as a Visiting Associate, Assistant Professor, Professor, and Director. Dr. Arnold’s laboratory focuses on protein engineering by directed evolution, with applications in alternative energy, chemicals, and medicine. She is the recipient of numerous honors, including induction into the National Inventors Hall of Fame, Fellow of the National Academy of Inventors, the ENI Prize in Renewable and Nonconventional Energy, the U.S. National Medal of Technology and Innovation, and the Charles Stark Draper Prize of the U.S. National Academy of Engineering. Dr. Arnold is an elected member of all three U.S. National Academics of Science, Medicine, and Engineering, as well as the American Academy of Arts and Sciences. Dr. Arnold received a B.S. in mechanical and aerospace engineering from Princeton University and a Ph.D. in chemical engineering from the University of California, Berkeley.

Daniel Bradbury

Mr. Daniel Mark Bradbury is an Independent Director of Illumina Inc. since January 2004. Mr. Bradbury served as Chief Executive Officer of Amylin Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, from 2007 until its acquisition by Bristol-Myers-Squibb Company in 2012. From 2006 until 2012, he was a member of Amylin’s board of directors and served on its Finance and Risk Management Committee. Mr. Bradbury also served as Amylin’s President (2006-2007), Chief Operating Officer (2003-2006), and Executive Vice President (2000-2003). He joined Amylin in 1994 and also held officer-level positions in Corporate Development and Marketing. From 1984 to 1994, Mr. Bradbury held a number of sales and marketing positions at SmithKline Beecham Pharmaceuticals, a global pharmaceutical manufacturer. Mr. Bradbury serves as a director of Corcept Therapeutics Incorporated, a NASDAQ-listed biopharmaceutical company, Geron Corporation, a NASDAQ-listed biopharmaceutical company, BioMed Realty Trust, Inc. a NYSE-listed real estate investment trust, and Castle Biosciences Inc., a privately-held molecular diagnostics company. Mr. Bradbury also serves on the BioMed Ventures Advisory Committee, the Investor Growth Capital Advisory Committee, the Keck Graduate Institute’s Board of Trustees, the UCSD Rady School of Management’s Advisory Council, the University of Miami’s Innovation Corporate Advisory Council, and the University of Miami’s Diabetes Research Institute Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education.

Karin Eastham

Ms. Karin Eastham, CPA, is Independent Director of Illumina, Inc. since July 2004. Ms. Eastham serves on the boards of directors for several life science companies. From May 2004 to September 2008, she served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research. From 1999 to 2004, Ms. Eastham served as Senior Vice President, Finance, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company. She previously held similar positions with CombiChem, Inc. a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Corporation, a biopharmaceutical company, from 1976 to 1988. Ms. Eastham also serves as a director for MorphoSys AG, a Frankfurt Stock Exchange-listed biotechnology company; Geron Corporation, a NASDAQ-listed biopharmaceutical company; Trius Therapeutics, Inc. a NASDAQ-listed biopharmaceutical company; and Veracyte, Inc. a privately-held molecular diagnostics company. Ms. Eastham also served as a past director of Amylin Pharmaceuticals, Inc. a NASDAQ-listed biopharmaceutical company, from 2005 until its sale to Bristol-Myers-Squibb Company in 2012; Genoptix, Inc. a NASDAQ-listed provider of specialized diagnostic laboratory services, from 2008 until its sale to Novartis AG in 2011; Tercica, Inc. a NASDAQ-listed biopharmaceutical company, from 2003 until its sale to Beaufour Ipsen Pharma in 2008; and SGX Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, from 2005 until its sale to Eli Lilly and Company in 2008. Ms. Eastham received a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant.

Robert Epstein

Dr. Robert S. Epstein, M.D. is Independent Director of Illumina, Inc. since November 29, 2012. Dr. Epstein is an epidemiologist who worked in public health and academia before joining the private sector. Prior to this role, Dr. Epstein was Medco’s Chief Medical Officer for 13 years, where he led formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting. Dr. Epstein is also the former President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the board of directors of the Drug Information Association (DIA) and the International Society of Quality of Life. Dr. Epstein serves as a director of AVEO Pharmaceuticals, Inc. a NASDAQ-listed cancer therapeutics company, and Proteus Digital Health, a privately-held healthcare technology company. Dr. Epstein has published more than 75 peer-reviewed medical articles and book chapters and serves as a reviewer for several influential medical journals, including the New England Journal of Medicine and JAMA (The Journal of the American Medical Association). Dr. Epstein received his medical degree and B.S. in Biomedical Science from the University of Michigan and an M.S. in preventative medicine from the University of Maryland.

Roy Whitfield

Mr. Roy A. Whitfield is Independent Director of Illumina, Inc. since January 2007. Mr. Whitfield is the former Chairman of the Board and Chief Executive Officer of Incyte Corporation (formerly Incyte Genomics), a NASDAQ-listed drug discovery and development company he co-founded in 1991. From 1993 to 2001, Mr. Whitfield served as its Chief Executive Officer and, from November 2001 until his retirement in June 2003, as its Chairman. Mr. Whitfield remains on the board of Incyte Corporation. From 1984 to 1989, Mr. Whitfield held senior operating and business development positions with Technicon Instruments Corporation, a medical instrumentation company, and its predecessor company, Cooper Biomedical, Inc., a biotechnology and medical diagnostics company. Earlier, Mr. Whitfield spent seven years with the Boston Consulting Group’s international consulting practice. In addition to serving on the Incyte Board, since 2000 he has served as a director of Nektar Therapeutics, a NASDAQ-listed clinical-stage biopharmaceutical company, and he also serves as a director of Station X Inc. a privately-held developer of software products for analyzing largescale human genome information. Mr. Whitfield also served as a past director of Solexa, Inc. from 2006 until its sale to Illumina in 2007. Mr. Whitfield received a B.S. in Mathematics from Oxford University and an M.B.A. from Stanford University.

Basic Compensation